Tazarotene/Clindamycin phosphate

他扎罗汀/磷酸克林霉素

Report date: 2026/05/09 20:00:18
NME

Base Information

Drug NameTazarotene/Clindamycin phosphate
Drug Alias Name他扎克林
ClassificationSmall molecules
Mechanisms of ActionRetinoic acid receptor gamma agonistsRetinoic acid receptor alpha agonistsRetinoic acid receptor beta agonists +[4] 
TargetsRetinoic acid receptor betaRetinoic acid receptor gammaRetinoic acid receptor alpha +[4] 
Therapy Area/IndicationsAcne VulgarisTuberculosis
Global Approved IndicationsTuberculosis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1971/06/02
Country/TerritoryUnited StatesMainland China
CombinationsYes TazaroteneClindamycin phosphate
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesJiangsu Sinomune Pharmaceutical Co LtdInstitute Of Dermatology, Chinese Academy Of Medical Sciences
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesInstitute Of Dermatology, Chinese Academy Of Medical SciencesChinese Academy of Medical Sciences Dermatology Hospital (Chinese Academy of Medical Sciences Dermatology Research Institute)China Resources Sanjiu Medical & Pharmaceutical Co Ltd +[4] 
Inactive CompaniesEpic Pharma Llc
Active IndicationsAcne Vulgaris
Inactive IndicationsTuberculosis

Other Information

ATC CodeN/A
Related LinksN/A